Pelthos Therapeutics Inc. Common Stock (PTHS)
Healthcare › Biological Products, (No Diagnostic Substances)
Price History
Feb 9, 2026 — May 24, 2026Investment Snapshot
- P/B of 2.64 — trading above book value
- Piotroski F-Score 5/9 — moderate financial health
- Loss-making — negative ROE of -90.9%
Pelthos Therapeutics Inc. Common Stock (PTHS) is a Healthcare company operating in Biological Products, (No Diagnostic Substances), listed on the AMEX , with a market capitalisation of $93 million . Key value metrics: P/B ratio 2.64, Piotroski F-Score 5 out of 9 (moderate financial health) .
Value Score
Key Metrics
Revenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
Pelthos Therapeutics Inc. Common Stock — Fundamental Analysis Summary
On financial health, PTHS shows a moderate Piotroski F-Score of 5/9, and negative return on equity of -90.9% (sector average: -20.6%), and elevated leverage with a debt-to-equity ratio of 1.17.
StockPik's composite Value Score for PTHS is 59/100 — an above-average value rating. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
PTHS reports a high gross margin of 76.3% (sector average: 40.1%) and a negative operating margin of -199.5%.
PTHS shows earnings declining at 445%.